Liquid biopsy enables the detection of resistance mutations, such as ESR1 mutations in hormone therapy-resistant breast cancer or HER2 mutations in trastuzumab-resistant cases, allowing for timely modifications in treatment strategy[68,69]. This evidence concerns the gene ERBB2 and breast cancer.